Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial
Study context
- Population
- Hospitalised COVID-19 patients
- Participants
- 385 patients
- Comparison
- Imatinib vs placebo
- Primary endpoint
- Incident severe hyperglycaemia
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Incidence of severe hyperglycaemia
- Significantly lower with imatinib
Further findings
Insulin production and central insulin sensitivity
- Unaffected by imatinib
Plasma biomarkers
- Imatinib increased angiotensin-2 and adiponectin, decreased JNK1, JNK2 and interleukin-6
Outcomes of patients with vs without severe hyperglycaemia
- Similar demographics; longer hospital stay, higher invasive ventilation and mortality rates with severe hyperglycaemia
Original publication
Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial. Crit Care. Published 29 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →